Champions Oncology (NASDAQ:CSBR) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Champions Oncology, Inc. (NASDAQ:CSBR)’s share price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $6.37 and traded as low as $5.70. Champions Oncology shares last traded at $5.85, with a volume of 20,938 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Champions Oncology Stock Down 0.3%

The stock has a market capitalization of $81.26 million, a PE ratio of -36.56 and a beta of 0.42. The firm has a 50 day moving average price of $5.97 and a 200 day moving average price of $6.37.

Institutional Trading of Champions Oncology

Several institutional investors and hedge funds have recently modified their holdings of CSBR. Goldman Sachs Group Inc. purchased a new stake in shares of Champions Oncology in the first quarter worth approximately $201,000. Jane Street Group LLC purchased a new stake in shares of Champions Oncology in the first quarter worth approximately $200,000. Acadian Asset Management LLC raised its stake in shares of Champions Oncology by 28.7% in the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 8,814 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Champions Oncology in the second quarter worth approximately $103,000. Finally, Vanguard Group Inc. raised its stake in shares of Champions Oncology by 1.9% in the third quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock worth $2,158,000 after purchasing an additional 6,229 shares during the last quarter. 41.30% of the stock is owned by hedge funds and other institutional investors.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.